logo
Медицинский вестник
Северного Кавказа
Научно-практический журнал
Зарегистрирован в Федеральной службе
по надзору за соблюдением законодательства
в сфере массовых коммуникаций
и охране культурного наследия
ПИ №ФС77-26521 от 7 декабря 2006 года
ISSN 2073-8137
rus
русский
eng
english

Поиск по сайту




Адрес редакции
355017, Ставрополь, улица Мира, 310.

Телефоны
(8652) 35-25-11, 35-32-29.

E-mail
medvestnik@stgmu.ru

Рейтинг@Mail.ru

Тактика лечения острого коронарного синдрома при первичной иммунной тромбоцитопении

[Обзор]
Дворецкий Леонид Иванович; Резван Владимир Владимирович;

Обзор литературы посвящен тактике лечения больных острым коронарным синдромом при тромбоцитопении.

Скачать

Список литературы:
1. Меликян А. Л., Пустовая Е. И., Цветаева Н. В., Абдулкадыров К. М., Лисуков И. А. [и др.]. Национальные клинические рекомендации по диагностике и лечению первичной иммунной тромбоцитопении (идиопатической тромбоцитопенической пурпуры) у взрослых. Гематология и трансфузиология. 2015;60(1):44-56.
2. Ilnicki D., Wyderka R., Nowicki P., Sołtowska A., Adamowicz J. [et al.]. A 64-year-old man suffering from ST-elevation myocardial infarction and severe thrombocytopenia: Procedures in the case of a patient not fitting the guidelines. SAGE Open Med. Case Rep. 2019;7:2050313X19840520. https://doi.org/10.1177/2050313X19840520
3. Rodeghiero F. Is ITP a thrombophilic disorder? Am. J. Hematol. 2016;91(1):39-45. https://doi.org/10.1002/ajh.24234
4. Doobaree I. U., Nandigam R., Bennett D., Newland A.,Provan D. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Eur. J. Haematol. 2016;97(4):321-330. https://doi.org/10.1111/ejh.12777
5. Takagi S., Suzuki I., Watanabe S. Risk of Thromboembolism in Patients with Immune Thrombocytopenia J. Hematol. Thromb. Dis. 2015;3:1. https://doi.org/10.4172/2329-8790.1000185
6. Ekstrand C., Linder M., Baricault B., Lafaurie M., Sailler L. [et al.]. Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia – Results from two nationwide cohorts. Thromb. Res. 2019;178:124-131. https://doi.org/10.1016/j.thromres.2019.04.016
7. Langeberg W., Schoonen W., Eisen M., Gamelin L., Stryker S. Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies. Int. J. Hematol. 2016;103:655-664. https://doi.org/10.1007/s12185-016-1974-6
8. Rodeghiero F. ITP and thrombosis: an intriguing association. Blood Adv. 2017;1(24):2280. https://doi.org/10.1182/bloodadvances.2017007989
9. Norgaard M., Cetin K., Maegbaek M. L., Kristensen N., Ghanima W. [et al.]. Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: A Scandinavian population-based cohort study. Br. J. Haematol. 2015;174(4):493-651. https://doi.org/10.1111/bjh.13787
10. Negash M., Tsegaye A., Medhin A. G. Diagnostic predictive value of platelet indices for discriminating hypo productive versus immune thrombocytopenia purpura in patients attending a tertiary care teaching hospital in Addis Ababa, Ethiopia. BMC Hematology. 2016;16:1-8. https://doi.org/10.1186/s12878-016-0057-5
11. Li-Sha G., Peng C., Yue-Chun L. Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review. BMC Cardiovasc. Disord. 2015;15:101. https://doi.org/10.1186/s12872-015-0092-3
12. Ranjith M. P., DivyaRaj R., Mathew D., George B., Krishnan M. N. Mean platelet volume and cardiovascular outcomes in acute myocardial infarction. Heart Asia. 2016;8(1):16-20. https://doi.org/10.1136/heartasia-2015-010696
13. Shah B., Valdes V., Nardi M. A., Hu L., Schrem E., Berger J. S. Mean platelet volume reproducibility and association with platelet activity and anti-platelet therapy. Platelets. 2014;25(3):188-192. https://doi.org/10.3109/09537104.2013.793794
14. Álvarez‑Román M. T., Fernández‑Bello I., Jiménez‑Yuste V., Martín‑Salces M., Arias‑Salgado E. G. [et al]. Procoagulant profile in patients with immune thrombocytopenia. Br. J. Haematol. 2016;175:925-934. https://doi.org/10.1111/bjh.14412
15. Jain A., Saluja S., Chaudhry S., Gupta D. K. Recurrent Arterial and Venous Thrombosis in Chronic Immune Thrombocytopenia: Clinical Paradox and Therapeutic Challenges. Indian J. Hematol. Blood Transfus. 2019;35(3):590-592. https://doi.org/10.1007/s12288-019-01136-3
16. Yusuf S. W., Iliescu C., Bathina J. D., Daher I. N., Durand J. B. Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. Tex. Heart Inst. J. 2010;37:336-340.
17. Hamilos M., Petousis S., Parthenakis F. Interaction between platelets and endothelium: from pathophysiology to new therapeutic options. Cardiovasc. Diagn. Ther. 2018;8(5):568-580. https://doi.org/10.21037/cdt.2018.07.01
18. Rungjirajittranon T., Owattanapanich W. A serious thrombotic event in a patient with immune thrombocytopenia requiring intravenous immunoglobulin: a case report. J. Med.Case Rep. 2019;13(1):25. https://doi.org/10.1186/s13256-018-1955-x
19. Catala-Lopez F., Corrales I., de la Fuente-Honrubia C. González-Bermejo D., Martín-Serrano G. [et al.]. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials. Med. Clin. (Barc.). 2015;145(12):511-519.
20. Thai L. H., Mahevas M., Roudot-Thoraval F., Limal N.,Languille L. [et al.]. Long-term complications of splenectomy in adult immune thrombocytopenia. Medicine (Baltimore). 2016;95(48):5098. https://doi.org/10.1097/MD.0000000000005098
21. Spath P. J., Granata G., La Marra F., Kuijpers T. W., Quinti I. On the dark side of therapies with immunoglobu lin concentrates: the adverse events. Front Immunol. 2015;6:11. https://doi.org/10.3389/fimmu.2015.00011
22. Kumar M., Panigrahi A., Mondal P., De R., Datta S. [et al.] Inherited and acquired thrombophilia as a modifier of clinical course of chronic immune thrombocytopenia. J. Appl. Hematol. 2020;11:336. https://doi.org/10.4103/joah.joah759
23. Balitsky A., Kelton J., Arnold D. Managing antithrombotic therapy in immune thrombocytopenia: development of the TH2 risk assessment score. Вlood. 2018;132(25):2684. https://doi.org/10.1182/blood-2018-08-868406
24. Yadav M., Genereux P., Giustino G., Madhavan M. V., Brener S. J. [et al.]. Effect of baseline thrombocytopenia on ischemic outcomes in patients with аcute coronary syndromes who undergo percutaneous coronary intervention. Canadian J. Cardiology. 2016;32:226-233. https://doi.org/10.1016/j.cjca.2015.05.020
25. Wang T. Y., Ou F. S., Roe M. T., Harrington R. A., Ohman E. M. [et al.]. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. Circulation. 2009;12;119(18):2454-2462. https://doi.org/0.1161/CIRCULATIONAHA.108.827162
26. Liu S., Song C., Zhao Y., Guan C., Zhu C. [et al.]. Impact of baseline thrombocytopenia on the long-term outcome of patients undergoing elective percutaneous coronary intervention: An analysis of 9,897 consecutive patients. Catheter Cardiovasc. Interv. 2019;93(1):764-771. https://doi.org/10.1002/ccd.28030
27. Shiraishi J., Koshi N., MatsubaraY., Nishimura T., Ito D. [et al.]. Effects of Baseline Thrombocytopenia on In-hospital Outcomes in Patients Undergoing Elective Percutaneous Coronary Intervention. Intern. Med. 2019;58:1681-1688. https://doi.org/10.2169/internalmedicine.2063-18
28. Copley A. L., Robb T.P., The effect of heparin in vivo on the platelet count in mice and dogs. Am. J. Clin. Pathol. 1942;12(11):563-570. https://doi.org/10.1093/ajcp/12.11.563
29. Weismann R. E., Tobin R. W. Arterial embolism occurring during systemic heparin therapy. AMA Arch. Surg. 1958;76(2):219-227. https://doi.org/10.1001/archsurg.1958.01280200041005
30. Natelson E. A., Lynch E. C., Alfrey C. P. Jr., Gross J. B. Heparin-induced thrombocytopenia. An unexpected response to treatment of consumption coagulopathy. Ann. Intern. Med. 1969;71(6):1121-5. https://doi.org/10.7326/0003-4819-71-6-1121
31. Rhodes G. R., Dixon R. H., Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestation. Surg. Gynecol. Obstet. 1973;136(3):409-416.
32. Fathi M. Heparin-induced thrombocytopenia (HIT): Identification and treatment pathways. Glob. Cardiol. Sci. Pract. 2018;2018(2):15. https://doi.org/10.21542/gcsp.2018.15
33. Salter B., Weiner M., Trinh M., Heller J., Evans A. [et al.]. Heparin-induced thrombocytopenia. A comprehensive clinical review. JACC 2016;67(21): 2519-2532. https://doi.org/10.1016/j.jacc.2016.02.073
34. Arepally G. M. Heparin-induced thrombocytopenia. Blood. 2017;129(21):2864-2872. https://doi.org/10.1182/blood-2016-11-709873
35. Rollin J., Pouplard C., Gruel Y. Risk factors for heparin-induced thrombocytopenia: Focus on Fcγ receptors. Thromb. Haemost. 2016;116:799. https://doi.org/10.1160/TH16-02-0109
36. Johnston I., Sarkar A., Hayes V., Koma G. T., Arepally G. M. [et al.]. Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation. Blood. 2020;135:1270. https://doi.org/10.1182/blood.2018881607
37. Foord A., Hoang J., Hsieh L., Nugent D. J. A new look into childhood acute ITP: The relationship between thrombin generation and thrombocytopenia. Blood. 2015;126:1058.
38. Greinacher A. Clinical Practice. Heparin-Induced Thrombocytopenia. N. Engl. J. Med. 2015;373(3):252-261. https://doi.org/10.1056/NEJMcp1411910
39. Salter B. S., Weiner M. M., Trinh M. A., Heller J., Evans A. S. [et al.]. Heparin-Induced Thrombocytopenia A Comprehensive Clinical Review. J. Am. Coll. Cardiol. 2016;67(21):2519-2532. https://doi.org/10.1016/j.jacc.2016.02.073
40. Bennett C. L., Weinberg P. D., Rozenberg-Ben-Dror K. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann. Intern. Med. 1998;128:541-544.
41. Rubano J. A., Chen K., Sullivan B., Vosswinkel J. A., Jawa R. S. Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura following Endovascular Treatment of Spontaneous Carotid Artery Dissection. J. Neurol. Surg. Rep. 2015;76(2):287-290. https://doi.org/10.1055/s-0035-1566127
42. Sareen R., Kapil M., Mathur P., Sharma M. Clopidogrel-induced thrombotic thrombocytopenia after years of medication. Int. J. Clin. Correl. 2018;2:31-33. https://doi.org/10.4103/ijcpc.ijcpc_3_18
43. Jacob S., Dunn B., Oureshi Z., Bandarenko N., Kwan H. [et al.]. Ticlipidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: A 20Year Review from the Southern Network on Adverce Reactions (SONAR). Semin. Thromb. Hemost. 2012;38(8):845-853. https://doi.org/10.1055/s-0032-1328894
44. Dogan A., Ozdemir B., Bal H., Özdemir E., Kurtoğlu N. Ticagrelor-associated thrombotic thrombocytopenic purpura. Anatol. J. Cardiol. 2017;17:73-74. https://doi.org/10.14744/AnatolJCardiol.2017.7426
45. Siao W. Z., Chuang W. Y., Su C. H., Huang S. F., Tu W. K., Chan K. C. A rare case of ticagrelor isolated thrombocytopenia. Acta Cardiol. Sin. 2017;33:556-558. https://doi.org/10.6515/ACS20161021C
46. Wang X., Zhang S., Li L., Hua J., Zhu L. [et al.]. Ticagrelor-induced thrombotic thrombocytopenic purpura. A case report and review of the literature. Medicine. 2018;97:26. https://doi.org/10.1097/md.0000000000011206
47. Ravikaran P., Ankur S., Daniel R., Suchit K., Bernard T. [et al.]. Severe Thrombocytopenia Due to Intravenous Tirofiban Therapy. Am. J. Ther. 2019;26 (4):534-537. https://doi.org/10.1097/MJT.0000000000000756
48. Golden T., Ghazala S., Wadeea R., Junna S. Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention. BMJ Case Rep. 2017;2017: bcr2017221182. https://doi.org/10.1136/bcr-2017-221182
49. Viswanathan G., Kidambi A., Nelson A., Mayurathan G., Hardy J. [et al.]. Glycoprotein IIb/IIIa inhibitor associated severe thrombocytopenia in patients with coronary artery disease: Clinical course and outcomes. Platelets. 2012;23(3):224-228. https://doi.org/10.3109/09537104.2011.604804
50. Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation – Web Addenda. Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2016;37(3):267-315. https://doi.org/10.1093/eurheartj/ehv320
51. Сумароков А. Б., Бурячковская Л. И., Ломакин Н. В. Тромбоцитопения и предстоящее эндоваскулярное вмешательство у больного ИБС. Медицинский Совет. 2018;21. https://doi.org/10.21518/2079-701X-2018-21-16-21
52. McCarthy C., Steg Ph., Bhatt D. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. Eur. Heart J. 2017;38:3488-3492. https://doi.org/10.1093/eurheartj/ehx531

Ключевые слова: первичная иммунная тромбоцитопения, острый коронарный синдром


Учредители:
Ставропольская государственная медицинская академия
Государственный научно-исследовательский институт курортологии
Пятигорская государственная фармацевтическая академия